PACB Pacific Biosciences Of California Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PACB

Price (delayed)

$8.3

Market cap

$2.05B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.4

Enterprise value

$2.67B

Pacific Biosciences of California, Inc. is empowering life scientists with highly accurate long-read sequencing. The company's innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a ...

Highlights
The quick ratio has plunged by 80% YoY and by 71% from the previous quarter
PACB's net income has shrunk by 73% YoY and by 5% QoQ
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.pacb.com
Peers: ILMN NSTG PKI TMO

Key stats

What are the main financial stats of PACB
Market
Shares outstanding
247.08M
Market cap
$2.05B
Enterprise value
$2.67B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.33
Price to sales (P/S)
14.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.83
Earnings
Revenue
$128.3M
EBIT
-$299.56M
EBITDA
-$282.24M
Free cash flow
-$279.96M
Per share
EPS
-$1.4
Free cash flow per share
-$1.25
Book value per share
$2.49
Revenue per share
$0.57
TBVPS
$4.22
Balance sheet
Total assets
$1.77B
Total liabilities
$1.2B
Debt
$946.64M
Equity
$562.9M
Working capital
$588.74M
Liquidity
Debt to equity
1.68
Current ratio
3.24
Quick ratio
3.01
Net debt/EBITDA
-2.2
Margins
EBITDA margin
-220%
Gross margin
38.2%
Net margin
-244.9%
Operating margin
-237.6%
Efficiency
Return on assets
-17%
Return on equity
-48.2%
Return on invested capital
-19.8%
Return on capital employed
-19.9%
Return on sales
-233.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PACB stock price

How has the Pacific Biosciences Of California stock price performed over time
Intraday
-6.11%
1 week
0%
1 month
-20.57%
1 year
-24.06%
YTD
1.47%
QTD
1.47%

Financial performance

How have Pacific Biosciences Of California's revenue and profit performed over time
Revenue
$128.3M
Gross profit
$49.04M
Operating income
-$304.82M
Net income
-$314.25M
Gross margin
38.2%
Net margin
-244.9%
The net margin has dropped by 76% year-on-year and by 12% since the previous quarter
PACB's net income has shrunk by 73% YoY and by 5% QoQ
PACB's operating margin is down by 48% year-on-year and by 14% since the previous quarter
The company's operating income fell by 46% YoY and by 7% QoQ

Growth

What is Pacific Biosciences Of California's growth rate over time

Valuation

What is Pacific Biosciences Of California stock price valuation
P/E
N/A
P/B
3.33
P/S
14.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.83
The EPS has plunged by 57% YoY and by 2.9% from the previous quarter
The P/B is 66% below the 5-year quarterly average of 9.7 but 39% above the last 4 quarters average of 2.4
The company's equity fell by 29% YoY and by 10% QoQ
The price to sales (P/S) is 30% lower than the 5-year quarterly average of 20.8 but 26% higher than the last 4 quarters average of 11.5
The revenue has decreased by 6% QoQ

Efficiency

How efficient is Pacific Biosciences Of California business performance
PACB's ROA has plunged by 53% YoY and by 8% from the previous quarter
The ROE has contracted by 44% YoY and by 14% from the previous quarter
The company's return on invested capital fell by 16% YoY and by 11% QoQ
The ROS has contracted by 16% YoY and by 13% from the previous quarter

Dividends

What is PACB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PACB.

Financial health

How did Pacific Biosciences Of California financials performed over time
The company's total assets is 47% higher than its total liabilities
The quick ratio has plunged by 80% YoY and by 71% from the previous quarter
The company's current ratio has shrunk by 79% YoY and by 71% QoQ
The debt is 68% greater than the equity
The company's debt to equity rose by 39% YoY and by 11% QoQ
The company's equity fell by 29% YoY and by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.